Skip to Content
Merck
  • Antiepileptic effects of exogenous β-hydroxybutyrate on kainic acid-induced epilepsy.

Antiepileptic effects of exogenous β-hydroxybutyrate on kainic acid-induced epilepsy.

Experimental and therapeutic medicine (2020-10-27)
Jianping Si, Yingyan Wang, Jing Xu, Jiwen Wang
ABSTRACT

The aim of the present study was to explore the potential anticonvulsant effects of β-hydroxybutyrate (BHB) in a kainic acid (KA)-induced rat epilepsy model. The KA-induced rat seizure model was established and BHB was administrated intraperitoneally at a dose of 4 mmol/kg 30 min prior to KA injection. Hippocampal tissues were then obtained 1, 3 and 7 days following KA administration, following which the expression levels of neuron-specific enolase (NSE) and glial fibrillary acidic protein (GFAP) were measured using a double immunofluorescence labeling method. In addition, the contents of glutathione (GSH), γ-aminobutyric acid (GABA) and ATP were measured using ELISA. Pretreatment with BHB markedly increased the expression of NSE after KA injection compared with that in the normal saline (NS) + KA group, suggesting that the application of BHB could alleviate neuronal damage in rats. The protective effect of BHB may be associated with suppressed inflammatory responses, which was indicated by the observed inhibition of GFAP expression in rats in the BHB + KA group compared with that in the NS + KA group. It was also found that GSH and GABA contents were notably increased after the rats were pretreated with BHB compared with those in the NS + KA group. To conclude, the application of exogenous BHB can serve as a novel therapeutic agent for epilepsy.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
DL-β-Hydroxybutyric acid sodium salt, ~98%
Sigma-Aldrich
Kainic acid monohydrate, ≥99% (TLC)